Longitudinal kinetics of human epididymis protein 4 in recurrent advanced ovarian carcinoma treated with platinum-based chemotherapy: mathematical modeling and prognostic implications

This publication has 27 references indexed in Scilit:

• ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer
  ESMO Open, 2026
• Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
  Annals of Oncology, 2023
• Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis
  European Journal of Cancer, 2023
• The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas
  Cancer Treatment Reviews, 2021
• Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate
  Cancer Chemotherapy and Pharmacology, 2020
• The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study
  Tumor Biology, 2015
• Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?
  Tumor Biology, 2014
• Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass
  Gynecologic Oncology, 2012
• Does HE4 have a role as biomarker in the recurrence of ovarian cancer?
  Tumor Biology, 2012
• HE4: a new potential early biomarker for the recurrence of ovarian cancer
  Tumor Biology, 2010